The need for increments up to the maximum dose in the UM/EM populations reflects the finding uncovered by Berard et al. [99], wherein the proportion of pregnant women with depression symptoms was higher in the UM/EM than in the PM CYP2D6 population even when treated with antidepressants. The gene discussed is CYP2D6; the disease is depressive symptom measurement.